Brought to you by 
Galena licenses gynecological cancer vaccine from MD Anderson and HJF
16 Nov 2021
Executive Summary
Galena Biopharma Inc. (oncology therapeutics) has licensed exclusive worldwide rights from the University of Texas MD Anderson Cancer Center and the Henry M. Jackson Fnd. Adv. Military Medicine (HJF) to develop and sell a folate binding protein E39 (FBP) vaccine for the prevention of the recurrence of gynecological cancers.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Large Molecule
- Immuno-Oncology
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Galena licenses gynecological cancer vaccine from MD Anderson and HJF
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice